ArticleAlzheimer's research & therapy2025
Dual risk of anticholinergic burden and CSF alzheimer's biomarkers in older patients: a mortality follow-up study from daily medical practice.
Article in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnticholinergic medications are widely prescribed to older adults and are linked to increased mortality and cognitive decline. Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD)-amyloid and tau-are strong prognostic indicators in neurocognitive disorders (NCD). However, it remains unclear whether anticholinergic burden amplifies mortality risk depending on CSF biomarker profiles in cognitively impaired individuals.
methodsWe conducted a retrospective monocentric study of 927 patients aged ≥ 65 years with mild or major NCD from a tertiary memory clinic in Paris, France. Participants underwent CSF biomarker assessment for amyloid (A), phosphorylated tau (T), and total tau (N), and were classified into ATN profiles. Anticholinergic burden was evaluated at baseline using the Anticholinergic Cognitive Burden (ACB) scale: none (ACB = 0), low-moderate (ACB = 1-2), or high (ACB ≥ 3). The primary outcome was all-cause mortality. Proportional hazards regression assessed associations between ACB, ATN profiles, and mortality, adjusting for demographic, clinical, and genetic covariates.
resultsHigh ACB was associated with increased mortality in model 1 (HR = 1.30, 95% CI: 1.03-1.64, p = 0.02), but not after full adjustment (HR = 1.26, 95% CI: 0.96-1.66, p = 0.09). ATN profiles remained strong independent predictors of mortality, with highest risks for A-T-N + and A + T + Nx profiles. Combined high ACB and abnormal biomarkers conferred greater risk than either alone (e.g., HR = 2.24 for A + T + Nx and high ACB).
conclusionAnticholinergic burden may increase vulnerability to mortality in older adults with an AD biomarker profile. These results support integrating pharmacological and biological risk factors into personalized dementia care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.